

would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Environmental Health Sciences Special Emphasis Panel: Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21).

*Date:* January 15, 2025.

*Time:* 11:30 a.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institute of Environmental Health Sciences, Keystone Building, 530 Davis Drive, Durham, NC 27709.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Murali Ganesan, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training (DETR), National Institute of Environmental Health Sciences, National Institutes of Health, Keystone Building, Room 3097, Research Triangle Park, NC 27713, Phone: 984-287-4674, Email: [murali.ganesan@nih.gov](mailto:murali.ganesan@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS)

Dated: December 12, 2024.

**Bruce A. George,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024-29836 Filed 12-17-24; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; Early-Stage Dissemination and Implementation Research in Communication Disorders.

*Date:* January 16, 2025.

*Time:* 12:30 p.m. to 4:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Andrea B. Kelly, Ph.D., Scientific Review Officer, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 6001 Executive Boulevard, Room 8351, Bethesda, MD 20892, (301) 451-6339, [kellya2@nih.gov](mailto:kellya2@nih.gov).

*Name of Committee:* National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; Inner Ear Imaging RFA Review.

*Date:* January 30, 2025.

*Time:* 1:30 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Kausik Ray, Ph.D., Scientific Review Officer, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 6001 Executive Blvd., Rockville, MD 20852, 301-402-3587, [rayk@nidcd.nih.gov](mailto:rayk@nidcd.nih.gov).

*Name of Committee:* National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; NIDCD Institutional Research Training Opportunities Review.

*Date:* January 31, 2025.

*Time:* 1:00 p.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Andrea B. Kelly, Ph.D., Scientific Review Officer, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 6001 Executive Boulevard, Room 8351, Bethesda, MD 20892, (301) 451-6339, [kellya2@nih.gov](mailto:kellya2@nih.gov).

*Name of Committee:* National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; NIDCD Clinical Research Center Grant (P50) Review.

*Date:* February 6, 2025.

*Time:* 1:00 p.m. to 4:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Kausik Ray, Ph.D., Scientific Review Officer, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, 6001 Executive Blvd., Rockville, MD 20852, 301-402-3587, [rayk@nidcd.nih.gov](mailto:rayk@nidcd.nih.gov).

*Name of Committee:* National Institute on Deafness and Other Communication

Disorders Special Emphasis Panel; Chemosensory Fellowship Review Meeting.

*Date:* February 11, 2025.

*Time:* 1:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Sonia Elena Nanesco, Ph.D., Scientific Review Officer, Division of Extramural Activities, NIDCD, NIH, 6001 Executive Blvd., Suite 8300, Bethesda, MD 20892, (301) 496-8683, [sonia.nanesco@nih.gov](mailto:sonia.nanesco@nih.gov).

*Name of Committee:* National Institute on Deafness and Other Communication Disorders Special Emphasis Panel; Hearing and Balance Fellowship Review.

*Date:* February 21, 2025.

*Time:* 12:00 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* Hilton Garden Inn Seaworld Orlando, FL.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Martin Basch, Ph.D., Scientific Review Officer, NIH/NIDCD, Scientific Review Branch, 6001 Executive Blvd., Suite 8300, Bethesda, MD 20892, (301) 496-9693, [martin.basch@nih.gov](mailto:martin.basch@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.173, Biological Research Related to Deafness and Communicative Disorders, National Institutes of Health, HHS)

Dated: December 12, 2024.

**Victoria E. Townsend,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024-29910 Filed 12-17-24; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; HEAL Initiative: Translating Research to Practice to End the Overdose Crisis.

*Date:* January 23–24, 2025.

*Time:* 10:30 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institute of Health  
National Institute on Drug Abuse, 301 North  
Stonestreet Avenue, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Sheila Pirooznia, Ph.D.,  
Scientific Review Officer, Scientific Review  
Branch, Division of Extramural Review,  
National Institute on Drug Abuse, NIH, 301  
North Stonestreet Avenue, MSC 6021,  
Bethesda, MD 20892, (301) 496–9350,  
[sheila.pirooznia@nih.gov](mailto:sheila.pirooznia@nih.gov).

*Name of Committee:* National Institute on  
Drug Abuse Special Emphasis Panel; NIDA  
REI: Research at Minority Serving  
Institutions on Neurocognitive Mechanisms  
Underlying the Impact of Structural Racism  
on the Substance Use Trajectory.

*Date:* February 3, 2025.

*Time:* 3:00 p.m. to 4:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institute of Health  
National Institute on Drug Abuse, 301 North  
Stonestreet Avenue, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Shareen Amina Iqbal,  
Ph.D., Scientific Review Officer, Scientific  
Review Branch, Division of Extramural  
Research, National Institute on Drug Abuse,  
NIH, 301 North Stonestreet Avenue, MSC  
6021, Bethesda, MD 20892, (301) 443–4577,  
[shareen.iqbal@nih.gov](mailto:shareen.iqbal@nih.gov).

*Name of Committee:* National Institute on  
Drug Abuse Special Emphasis Panel;  
Developing Digital Therapeutics for  
Substance Use Disorders.

*Date:* February 5, 2025.

*Time:* 1:00 p.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institute of Health  
National Institute on Drug Abuse, 301 North  
Stonestreet Avenue, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Shareen Amina Iqbal,  
Ph.D., Scientific Review Officer, Scientific  
Review Branch, Division of Extramural  
Research, National Institute on Drug Abuse,  
NIH, 301 North Stonestreet Avenue, MSC  
6021, Bethesda, MD 20892, (301) 443–4577,  
[shareen.iqbal@nih.gov](mailto:shareen.iqbal@nih.gov).

(Catalogue of Federal Domestic Assistance  
Program Nos. 93.277, Drug Abuse Scientist  
Development Award for Clinicians, Scientist  
Development Awards, and Research Scientist  
Awards; 93.278, Drug Abuse National  
Research Service Awards for Research  
Training; 93.279, Drug Abuse and Addiction  
Research Programs, National Institutes of  
Health, HHS)

Dated: December 12, 2024.

**Lauren A. Fleck,**

*Program Analyst, Office of Federal Advisory  
Committee Policy.*

[FR Doc. 2024–29831 Filed 12–17–24; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### The National Institutes of Health Public Access Policy

**AGENCY:** National Institutes of Health,  
HHS.

**ACTION:** Notice.

**SUMMARY:** The 2024 National Institutes  
of Health (NIH) Public Access Policy  
implements additional steps to  
accelerate free public access to scholarly  
publications resulting from the research  
that NIH supports, building upon NIH's  
long history of providing public access  
to research results.

#### FOR FURTHER INFORMATION CONTACT:

Hilary Leeds, J.D., Senior Policy Analyst  
for Public Access, Office of Science  
Policy, at (301) 496–9838 or  
[SciencePolicy@od.nih.gov](mailto:SciencePolicy@od.nih.gov).

#### SUPPLEMENTARY INFORMATION:

##### Background

Increasing access to publications  
resulting from the National Institutes of  
Health (NIH) funding offers many  
benefits to the scientific community and  
the public who funded the underlying  
research. When patients, families, and  
healthcare providers can access  
published findings resulting from NIH  
funding, they are able to better  
understand and address the most  
critical health concerns facing their  
communities. It also allows researchers,  
students, and members of the public in  
all communities to have equitable  
access to such content. This access can  
accelerate future research, lead to  
collaboration, and allow interested  
readers and patients to follow the latest  
advances more closely. Importantly,  
these goals reflect NIH's commitment to  
the responsible stewardship of the  
Nation's investment in biomedical  
research by improving transparency and  
accessibility of taxpayer-funded  
research, an essential component of  
fostering trust in research. NIH is  
issuing this updated Public Access  
Policy to further advance these goals by  
accelerating free public access to  
research results.

NIH has a long history of providing  
access to research products resulting  
from its funded research. The NIH  
Public Access Policy [https://  
sharing.nih.gov/public-access-policy/  
public-access-policy-overview](https://sharing.nih.gov/public-access-policy/public-access-policy-overview) in effect  
since 2008, requires that NIH-supported  
researchers submit their final peer-  
reviewed manuscripts to the National  
Library of Medicine's PubMed Central®  
digital archive of full-text biomedical

and life sciences journal literature upon  
acceptance for publication, to be made  
freely available to the public after an  
allowable embargo period of not more  
than 12 months after the official date of  
publication. The 2008 Policy  
implements Public Law 110–161  
[https://www.congress.gov/110/statute/  
STATUTE-121/STATUTE-121-  
Pg1844.pdf](https://www.congress.gov/110/statute/STATUTE-121/STATUTE-121-Pg1844.pdf), which was made a  
legislative mandate for FY 2009 and  
beyond by Public Law 111–8 [https://  
www.govinfo.gov/content/pkg/PLAW-  
111publ8/pdf/PLAW-111publ8.pdf](https://www.govinfo.gov/content/pkg/PLAW-111publ8/pdf/PLAW-111publ8.pdf). The  
Policy has, to date, resulted in more  
than 1.5 million articles reporting on  
NIH-supported research being freely  
available to the public in PubMed  
Central.

On August 25, 2022, the White House  
Office of Science and Technology Policy  
(OSTP) released updated policy  
guidance (2022 OSTP Memorandum  
[https://www.whitehouse.gov/wp-  
content/uploads/2022/08/08-2022-  
OSTP-Public-Access-Memo.pdf](https://www.whitehouse.gov/wp-content/uploads/2022/08/08-2022-OSTP-Public-Access-Memo.pdf)) to all  
federal agencies with research and  
development expenditures to further  
promote equity, advance trust in  
science, and continue to advance  
American scientific leadership.  
Following the 2022 OSTP  
Memorandum, NIH released its Plan to  
Enhance Public Access to the Results of  
NIH-Supported Research [https://  
grants.nih.gov/grants/guide/notice-files/  
NOT-OD-23-091.html](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-23-091.html) in February 2023  
(hereafter, the NIH Public Access Plan)  
and its Draft Public Access Policy  
[https://www.federalregister.gov/  
documents/2024/06/18/2024-13373/  
request-for-information-on-the-national-  
institutes-of-health-draft-public-access-  
policy](https://www.federalregister.gov/documents/2024/06/18/2024-13373/request-for-information-on-the-national-institutes-of-health-draft-public-access-policy) in June 2024 (NIH Draft Public  
Access Policy). The NIH Public Access  
Plan and Draft Public Access Policy  
provided a roadmap for how NIH  
proposed to accelerate access to  
scholarly publications, consistent with  
the government-wide expectation to  
remove the 12-month embargo period  
before public availability. This 2024  
NIH Public Access Policy is consistent  
with the expectations of the 2022 OSTP  
Memorandum regarding scholarly  
publications and is informed by all  
public feedback, including comments  
submitted in response to the NIH Draft  
Public Access Policy.

#### Overview of Public Comments

A total of 144 written public  
comments [https://osp.od.nih.gov/wp-  
content/uploads/2024/10/Compiled-  
Public-Comments-on-RFI-on-the-NIH-  
Draft-Public-Access-Policy-508C.pdf](https://osp.od.nih.gov/wp-content/uploads/2024/10/Compiled-Public-Comments-on-RFI-on-the-NIH-Draft-Public-Access-Policy-508C.pdf)  
were received in response to the NIH  
Draft Public Access Policy. Written  
comments were received from a variety